Lumateperone Added to Antidepressant Therapy in Adults With Major Depressive Disorder Experiencing Emotional Blunting
Part of paid clinical trials in State College, Pennsylvania.
- Sponsor
- Future Options Research, LLC
- Study ID
- NCT07824206
- Phase
- PHASE4
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Blunted Emotion in Major Depressive Disorder
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- lumateparone 42 mg once daily — DRUGlumateparone 42 mg once daily added to current antidepressant treatment
- lumateparone — DRUGLumateparone
Study Details
The purpose of this study is to evaluate whether or not adding lumateparone to current antidepressant treatment in adults with major depressive disorder experiencing blunted emotion will reduce or eliminate the blunted emotion as rated by the Oxford Depression Questionnaire.
Key Dates
- First listed
- Sep 17, 2026
- Start date
- Sep 30, 2026
- Status verified
- Sep 2026
- Primary completion
- Jan 31, 2028
- Completion
- Mar 31, 2028
Study Design
- Enrollment
- 30 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Other: LumateparoneInvestigation of addition of lumateparone for blunted emotion
Primary Outcome Measure
Change from baseline to week 8 in Oxford Depression Questionnaire score [ Time Frame: 8 weeks ]
Central Contacts
- Clinical Coordinator814-237-0001
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Future Options Research | State College | Pennsylvania | 16801 |
Find similar trials in State College, PA
By research site